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ABSTRACT 
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are 
hematologic malignancies that occur most frequently in the sixth and seventh decades of life. 
Both disorders are associated with a poor prognosis, with median survival of one year or less. An 
overall five-year survival rate for both disorders, regardless of treatment, is less than 10%. A 
primary goal of treatment is to improve quality of life (QOL) because cure is improbable. The 
purpose of this longitudinal cohort study was to compare QOL between groups, intensive, non-
intensive therapy, and supportive care. The sample consisted of 85 patients with high risk MDS 
and AML recruited from Moffitt Cancer Center. Functional Assessment of Cancer Therapy-
Leukemia (FACT-Leu) was used to measure QOL. The aims for the study were to: 1) To 
compare the difference in QOL scores measured by the Functional Assessment of Cancer 
Therapy –Leukemia version for intensive chemotherapy, non-intensive therapy and supportive 
care within 7 days of new treatment and one month after initiation of treatment; 2) To determine 
QOL predictors of AML and high risk MDS from age, comorbidity, fatigue, and diagnosis; 3) To 
test the moderating effect of treatment with age, comorbidity, and fatigue on QOL. 
The first aim was analyzed with repeated measures analysis of variance (ANOVA). The 
supportive care group was not included in the analysis because of low accrual. Results indicated 
that there was a significant group by time interaction (with p=.040). Follow up tests revealed that 
the intensive treatment group had a significant improvement in their QOL scores at 1 month post 
treatment (p=.020). The second aim was conducted using Pearson’s correlations with age, 
comorbidity, fatigue, and diagnosis with significant correlations found between fatigue and QOL 
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(r=-.693, p< .001). These findings identify an important relationship between fatigue and QOL. 
This was a negative correlation, showing that as fatigue increases QOL decreases. The third aim 
was explored using regression with Hayes (2013) application for moderation analysis. Scores for 
QOL for age, comorbidity, and fatigue were not moderated by treatment.  
These findings suggest that the most intensive treatment approach improves QOL. In 
addition, fatigue is a significant predictor of QOL. As fatigue increases, QOL scores decrease. 
Additional studies with a larger, more diverse sample is needed to explore the relationship 
between treatment approaches and QOL. In addition, intervention studies can be developed in 
AML and high risk MDS focused on fatigue management. It is anticipated that the results of this 
study will be used to inform patients and health care providers when making decisions 
concerning treatment based on QOL outcomes.
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CHAPTER ONE: 
 INTRODUCTION  
Patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome 
(MDS) face the difficult decision of choosing the best treatment approach, knowing that their 
prognosis is poor. Unfortunately, few studies are available to help health care providers guide 
patients in choosing treatments based on quality of life (QOL). 
 Both AML and MDS are bone marrow malignancies that occur commonly in older 
patients, in whom optimal treatment remains controversial (Klepin, Rao, & Pardee, 2014). 
Treatment can range from supportive care to hematopoietic stem cell transplant. The diseases are 
often studied together because they have similar disease characteristics, life expectancy (for 
high-risk disease), age, comorbidities, and treatment options (Klepin et al., 2014; Merkel et al., 
2013; Sekeres et al., 2004). The most common form of adult acute leukemia is AML with 
approximately 18,860 cases diagnosed and 10,460 deaths in 2014 (American Cancer Society, 
2014). The median age of diagnosis in the United States is 67 years, according to the National 
Cancer Institute Surveillance Epidemiology and End Results data (SEER, 2015). MDS incidence 
using a claims-based algorithm in conjunction with SEER data project approximately 50,000 
cases per year in the Unites States, with a median age of 76 years (Craig, Rollison, List, & 
Cogle, 2012). Approximately 20,000 cases of MDS are high risk (Ma, Does, Raza, & Mayne, 
2007). 
High risk MDS is determined by calculating an individual score, the International 
Prognostic System Score, from unique patient characteristics including number of cytopenias, 
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percentage of marrow blasts, and cytogenetic abnormalities (Greenberg et al., 1997). 
Determination of treatment is based on age, performance status, comorbidities, and patient 
preference (NCCN, 2015). High risk MDS and AML are treated in the same way, have a similar 
prognosis, and are grouped for comparison in this study. 
Treatment 
 Standard treatment for AML patients 60 years of age and older is based on performance 
status, prior hematologic disorder, presence of unfavorable cyogenetic or molecular 
abnormalities, and whether it is related to prior chemotherapy or radiation therapy (NCCN, 
2015). Treatment recommendations for patients with an Eastern Cooperative Oncology Group 
performance status of 0-2 include clinical trial, intense chemotherapy with induction 
chemotherapy, and non-intensive chemotherapy with azacitidine or decitabine. Clinical trial, 
non-intensive chemotherapy, and best supportive care are recommended for patients who have a 
performance status greater than two, or significant comorbidities, or are older than 75. Intense 
chemotherapy includes treatment with cytosine arabinoside and an anthracycline administered in 
the hospital, with an anticipated length of hospitalization of four to six weeks, and a cure rate of 
35% (Estey, 2006). The majority of AML and high-risk MDS patients are not able to tolerate 
hematopoietic stem cell transplant, which is the standard of care for many younger patients 
(Baron & Storb, 2007). According to SEER data (2015), the five-year relative survival rate from 
2007 to 2012 was 25.9% for adults. In contrast, the five-year disease free survival rates for AML 
patients 65 years of age and older was only 5%. Survival rates for older AML patients have not 
changed in the past three decades (Erba, 2007). Studies are ongoing to try to improve the overall 
survival and cure for this distinct population of patients (Burnett et al., 2010; Burnett, Wetzler, & 
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Lowenberg, 2011). In contrast, few studies have focused on the quality of their survival with 
different treatment approaches (Leach et al., 2006).  
The goal of treatment with high risk MDS is to maintain the best QOL and improve 
survival. Cure is impossible without an allogeneic stem cell transplant. The National 
Comprehensive Cancer Network (NCCN) recommends that age, performance status, and 
comorbities determine appropriate therapy (2015). Patients should receive supportive care, which 
includes evaluation of QOL, psychosocial support, transfusions with blood products when 
needed, and infection management (NCCN, 2015). Treatment recommendations for high risk 
MDS include low intensity therapy with a hypomethylating agent such as azacitidine or 
decitabine. Hypomethylating agents are administered in the outpatient setting monthly, for as 
long as the patient responds, or development of adverse side effects. Allogeneic stem cell 
transplant is considered if the patient is healthy, and has a human leukocyte antigen identical 
donor (NCCN, 2015; Giralt, Horowitz, Weisdorf, & Cutler 2011).  
The majority of AML and high risk MDS patients die within five years with or without 
standard treatment (Garcia-Manero, & Fenaux, 2011; Estey, 2007). To prevent unnecessary 
suffering, it is important to understand how the treatment influences QOL for these patients 
because cure is improbable. Earle et al. (2008) reviewed aggressive cancer care near the end of 
life. Patients with various malignancies continued to receive intensive chemotherapy within 14 
days of death in 17.1% of patients, and approximately 10% of patients remained hospitalized in 
the last month of life. The hematologic malignancies, such as AML and MDS, were most 
strongly associated with aggressive care. Additional findings included underutilization of 
hospice services; the National Cancer Policy Board (1999) defined this as poor-quality of care, 
when practices of known effectiveness are infrequently used. 
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Acute myeloid leukemia and high-risk MDS in older patients have a grim prognosis for 
several reasons. First, intensive chemotherapy is difficult for older individuals to survive because 
of comorbities, decreased clearance of chemotherapy from renal effects of aging, and poor 
tolerance of bacterial and fungal infections (Eleni, Nicholas, & Alexandros, 2010). Older AML 
patients do not respond to intensive chemotherapy, when compared to their younger counterparts 
from an increased proportion of unfavorable karyotype abnormalities in chromosomes 5, and 7, 
and complex chromosomal rearrangements in older AML patients. Karyotyping, also known as 
cytogenetics, grow from bone marrow aspirates to evaluate for acquired chromosomal 
abnormalities (Knipp, et al. 2007). Cytogenetic analysis depends on cells that are undergoing cell 
division, or mitosis. Abnormal acquired chromosomal changes in the older patients often 
translate into resistance to intensive chemotherapy (Applebaum, et al., 2006). Other factors that 
have been associated with resistance to chemotherapy in the older AML patients include the 
evolution of AML from antecedent hematologic disorders such as MDS, the presence of 
dysplastic changes, the frequent expression of the multidrug resistance phenotype and the 
involvement of more primitive progenitors in the leukemic process (Applebaum, et al., 2006). 
 Limited information is available concerning QOL for older AML and high-risk MDS 
patients (Sekeres, et al., 2004; Stone, 2002; Alibhai, et al., 2009). To date, the primary objective 
of clinical trials has been evaluation of response to treatment, length of hospitalization, overall 
survival, and the biology of the disease (Estey, 2009). Quality of life has been the secondary 
focus of a few clinical trials, utilizing various instruments (Joly, Vardy, Pintilie, & Tannock, 
2007). Quality of life becomes the focus of treatment when cure is impossible. If two treatments 
are equally efficacious, the one that results in a more favorable QOL should be chosen.  
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Quality of Life 
Quality of life is a subjective, personal experience. The most accurate measurements for 
QOL come from the patient (Gotay, Kawamoto, Bottomley, & Efficace, 2008). There is 
agreement concerning the multidimensional aspect of QOL; however, which dimensions to 
include in QOL assessments vary. Domains evaluated in QOL are physical, psychological, 
functional, and social. Some models include spiritual and emotional as separate domains (Harris, 
et al., 2010). In 1994, the World Health Organization (WHO) defined QOL as “individuals’ 
perceptions of their position in life in the context of the culture and the value system in which 
they live and in relation to their goals, standards, and concerns” (WHO, Definition section, para. 
1). Six domains of QOL are in the WHO definition including physical health, psychological 
health, and levels of independence, social relationships, environmental features, and spiritual 
concerns.  
 Intensive chemotherapy is less effective for older AML patients and is associated with 
significant toxicity resulting in fewer older patients receiving treatment. These small numbers 
make it difficult to evaluate response to treatment and QOL during the treatment (Fröhling, et.al, 
2006). Older AML and high-risk MDS patients also have higher rates of recurrent leukemia after 
achieving remission with intensive chemotherapy (Löwenberg, et al., 2010), and greater 
comorbidity (Rao & Cohen, 2004). On the opposite spectrum of treatment options, Koreth and 
colleagues (2011), found that reduced intensity stem cell transplant offered a life expectancy 
benefit, with adjustment for quality survival. 
Statement of the Problem 
Acute myeloid leukemia and high-risk MDS are hematologic malignancies that occur 
most frequently in the seventh and eighth decades of life. Without treatment, AML and high-risk 
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MDS are associated with a poor prognosis, with median survival of five to twelve months for 
high risk MDS, and eight months for AML. With treatment, survival is improved; but cure is 
rare, with five-year survival rates of less than 10%. Therefore, the goal of treatment is to improve 
QOL, and palliate symptoms. Unfortunately, QOL is not routinely evaluated. It is important to 
improve QOL in older AML patients by identification of the factors that contribute the most to 
improved QOL, because cure is improbable. Equally important is the need to identify treatments 
that tend to worsen QOL, to prevent unnecessary suffering. Definitive evidence is not available. 
Studies are needed which compare QOL with different treatment approaches, intense versus non-
intense, and the variables which predict for QOL with different approaches to treatment.  
Statement of the Purpose 
 The purpose of this observational longitudinal cohort study is to evaluate the impact of 
different treatments on QOL and evaluate predictors of QOL for older AML and high-risk MDS 
patients. The independent variables that will serve as predictors of QOL are diagnosis, age, 
comorbidities, and fatigue. The dependent variable is QOL. 
Specific Aims 
This study addresses the following aims: 
1.  To compare the difference in QOL scores measured by the Functional Assessment of Cancer 
Therapy –Leukemia version for intensive chemotherapy, non-intensive therapy, and 
supportive care within 7 days of new treatment and one month after initiation of treatment in 
older patients with AML or high risk MDS. 
2. To determine QOL predictors of AML and high-risk MDS from age, comorbidity, fatigue, 
and diagnosis. 
3. To examine the moderating effect of treatment with age, comorbidity, and fatigue on QOL. 
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Definition of Relevant Terms 
1. Acute myeloid leukemia- a clonal, malignant disease of hematopoietic tissues characterized by 
(1) accumulation of abnormal (leukemic) blast cells, principally in the marrow, and (2) impaired 
production of normal blood cells. Thus, the leukemic cell infiltration in marrow is accompanied, 
nearly invariably, by anemia, and thrombocytopenia. The absolute neutrophil count may be low 
or normal, depending on the total white cell count (Liesveld, & Lichtman, 2010). This includes 
the cytogenetic analysis, or the study of genetics at the chromosome level of the hematopoietic 
cells (Tsai, Manchester, & Elias, 2011). 
2. High-risk MDS- myelodysplasia is a term used to encompass a spectrum of clonal (neoplastic) 
myeloid disorders marked by ineffective hematopoiesis (exaggerated marrow cell apoptosis), 
cytopenias, qualitative disorders of blood cells and their precursors, clonal chromosomal 
abnormalities, and a variable predilection to undergo clonal evolution to AML (Liesveld, & 
Lichtman, 2010). This includes the cytogenetic analysis, or the study of genetics at the 
chromosome level of the hematopoietic cells (Tsai, Manchester, & Elias, 2011). 
3. Intensive chemotherapy- chemotherapy administered to induce bone marrow aplasia, which is 
administered in the hospital intravenously. This treatment requires a four to six-week 
hospitalization for transfusion and infection management (Estey, 2006). 
4. Comorbidity- concomitant but unrelated pathological or disease process. In this study, the 
number of comorbidities is measured using the Charlson Comorbidity Index (American Heritage 
Medical Dictionary, 2007). 
5. Hypomethylating agents- drugs that inhibits deoxyribonucleic acid methylation. Current 
approved medications include azacitidine and decitabine (Sekeres, et al., 2004). 
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6. Best supportive care- care given to improve the QOL of patients who have a serious or life-
threatening disease. The goal of supportive care is to prevent or treat as early as possible the 
symptoms of a disease, side effects caused by treatment of a disease, and psychological, social, 
and spiritual problems related to a disease or its treatment. Best supportive care is also called 
comfort care, palliative care, and symptom management (National Cancer Institute, 2013). 
Assumptions  
Several assumptions of this study are implicit. First, patients will choose the best 
treatment if they know how it affects the quality of their survival. Next, the study setting 
influences QOL evaluations. Inpatients may rate their QOL differently than outpatients. In 
addition, patients will evaluate their QOL accurately and honestly, which provides QOL data for 
individuals with similar diagnoses considering treatment.  
Significance of the Study 
The significance of this study is that it provides information on QOL for patients with 
high-risk MDS and AML. Because of this study, when faced with treatment choices the patient 
and caregiver may have more information to guide the best treatment approach. In addition, 
valuable information was obtained from the QOL measures regarding how the individual factors, 
such as age, comorbidity, and level of fatigue affect QOL. Increased knowledge of the impact of 
the factors can guide further studies focused on areas that can improve QOL. The development 
of predictive QOL models and individual predictors of QOL can help patients and health care 
providers select the most appropriate, personalized treatment, and provide a foundation for future 
QOL research in this patient population. 
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CHAPTER TWO: 
 REVIEW OF LITERATURE 
 The purpose of this chapter is to review and synthesize the current evidence of the 
determinants of QOL of older patients with high-risk MDS and AML. Searches of Medline, 
CINAHL, and PubMed were conducted for each of the measured variables including age, 
fatigue, comorbidity, treatment, and QOL in patients with high-risk MDS and AML. Manual 
searches of article references were included for relevant studies to include in the literature 
review, including research studies published on QOL in high-risk MDS and AML in the last 10 
years. Peer reviewed manuscripts with the key terms MDS, QOL, and AML were analyzed for 
content validity, scientific rigor, and relevance to the current investigation. Then, the additional 
variables of age, co-morbidities, and fatigue were searched in combination with cancer and QOL. 
First, the theoretical framework is introduced; it guided integration of the variables of interest 
into QOL for patients with high-risk MDS and AML. Subsequently, empirical studies related to 
high-risk MDS and QOL were synthesized and highlight the current knowledge of QOL in AML 
and high-risk MDS. Finally, knowledge gaps are identified and the identification of where 
additional research is needed. 
Theoretical Background 
There is agreement concerning the multidimensional aspect of QOL, and that individuals 
are the best judges of their QOL. However, which dimensions to include in QOL assessments 
vary. Domains commonly evaluated include physical, psychological, functional, and social. 
Cella and colleagues (1993) included emotional well-being, social/family well-being, functional 
  
10 
 
well-being, and physical well-being in the Functional Assessment of Cancer Therapy (FACT). In 
1994, the WHO defined QOL as “individuals’ perceptions of their position in life in the context 
of the culture and the value system in which they live and in relation to their goals, standards, 
and concerns” (WHO, Definition section, para.1). Six domains of QOL are in the WHO 
definition, including physical health, psychological health, and levels of independence, social 
relationships, environmental features, and spiritual concerns.  
Age for High-Risk MDS and AML Patients 
 Both AML and MDS are malignancies primarily of older people. The peak incidence of 
AML is 67 years (SEER, 2015). Similarly, MDS occurs most commonly at 60-69 years 
(Shadduck, Latsko, Rossetti, Haq, & Abdulhaq, 2007). Survival rates are inferior in the greater 
than 60 age group for AML. It is unclear why survival rates are inferior, but the inability for 
older patients to tolerate the treatment has been proposed as an explanation for inferior survival 
rates. Special consideration is necessary when treating older patients with chemotherapy because 
of deterioration in organ function associated with advanced age (Lichtman, & Boparai, 2008). In 
addition, there are age-related changes in the metabolism of medications that require dose 
modifications. Anthracyclines, key drugs in the treatment of AML, require dose adjustment in 
patients greater than 60 years because of the association with cardio toxicity (Wojtacki, Lewicka-
Nowak, & Les´niewski-Kmak., 2000). This dose modification affects survival. An explanation 
for poorer outcomes in older patients is the association between older age and poor performance 
status, comorbidities, treatment related AML (from prior chemotherapy or radiation), and most 
important, specific cytogenetic abnormalities (Applebaum et al., 2006; Wheatley, et al., 2009). 
Age has been studied as a prognostic indicator for survival, and to help determine the most 
appropriate therapy (Walter, Othus, Borthakur, et al., 2010). Thus far, evidence could not be 
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found for how age predicts QOL in patients with AML and MDS. Age is a major consideration 
for determining appropriate treatment, because advanced age adversely affects survival with 
conventional, intense chemotherapy. 
 Selecting effective treatment for AML and MDS in the elderly remains a challenging 
task. The biology of AML in older patients is different from patients younger than 60 years. 
Older AML patients have unfavorable chromosomes in the cytogenetic analysis of their bone 
marrow, which means they have more aggressive AML that is notoriously resistant to standard 
chemotherapy (Applebaum, et al., 2006). In addition, MDS is a disease almost entirely of elderly 
patients. When the disease progresses to AML, it is usually resistant to standard chemotherapy 
(Walter, et al., 2012).  
Fatigue for High-Risk MDS and AML Patients 
Patients with AML and MDS typically present to the healthcare system with symptoms 
related to anemia (Estey, 2012; Balducci, 2006). Other common problems for MDS and AML 
patients are bone marrow failure, and resultant complications (Estey, 2012). Profound fatigue, 
recurrent infections, bleeding, bruising, and shortness of breath are symptoms reported by MDS 
patients (Hofmann, & Koeffler, 2005). Steensma et al. (2008) in a 120- question Internet survey 
of 359 respondents reported excessive fatigue as the most common symptom reported by MDS 
patients. Fatigue had a negative impact on QOL, not correlated with hemoglobin levels. 
Instruments used in the Internet survey included the FACT-Anemia and the Brief Fatigue 
Inventory (BFI). Similarly, Schumacher, Kessler, Buchner, Wewers, & Van de Lou (1998) 
conducted prospective, repeated measures, longitudinal study to determine QOL for patients 
undergoing chemotherapy, according to the German AML Cooperative Group. Quality of life 
was measured at 12 different time points using the European Organisation for Research and 
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Treatment of Cancer Quality of Life Questionnaire –Core 30 (EORTC QLQ- C30; Aaronson et 
al., 1993). Sixty-one patients enrolled during the first 30 months of the study. Only 28 patients 
were alive, and able to complete all 12 measurements. For the patients who survived the 
treatment, emotional functioning and social functioning improved significantly by the end of 
treatment. In addition, fatigue was closely related to QOL, as measured by the EORTC QLQ-
C30 subscale for fatigue, with QOL declining as fatigue increased. This study also found fatigue 
to have a low correlation with hemoglobin level. Oliva et al. (2011) conducted a prospective 
observational study to investigate changes in QOL scores and their association with therapy and 
survival in elderly patients with AML. One-hundred and thirteen patients enrolled. Forty-eight 
patients received intensive chemotherapy, and 65 received palliative treatment. Two different 
QOL instruments were administered, which included the EORTC QLQ-C30 and a health-related 
QOL questionnaire for patients with hematologic diseases named QOL-E. Survival was 
independently predicted by QOL-E functional (p=0.002) and EORTC QLQC-C30 physical 
(p=0.030) scores. In multivariate analysis both hemoglobin and age independently predicted 
fatigue (R2 0.114, P=0.001) and (R2 0.066, P=0.01) respectively. From these studies, there is 
evidence that fatigue is a rational predictor of QOL for AML and high-risk MDS.  
Comorbidities and QOL 
 With advancing age the number and severity of comorbidities increase, and makes 
treatment decisions more difficult (Applebaum et al., 2006). It also makes teasing out the 
etiology of symptoms complicated. Wedding et al. (2007) evaluated global QOL in 477 patients 
to measure how functional impairment and co morbidity influence QOL. From this group, 195 
were cancer patients aged 60 years or older (group A), 152 were cancer patients below the age of 
60 years (group B), admitted as inpatients for chemotherapy initiation and 130 patients were 
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aged 60 years or older admitted for disorders unrelated to cancer (group C). The EORTC QLQ-
C30 measured QOL. The Karnofsky Performance Scale (KPS) and the Instrumental Activities of 
Daily Living (IADL) scale measured functional status. Finally, the Cumulative Illness Rating 
Scale assessed comorbidity. In this study, the IADL and KPS independently contributed to 
global QOL, with patients experiencing lower scores for IADL and KPS having decreased global 
QOL scores. In addition, comorbidity contributed to global QOL in elderly cancer patients.  
Oliva et al. (2011), in a prospective observational study evaluated changes in QOL scores 
and their association with therapy and survival in elderly patients with AML. The analysis 
included comorbidity data. Concomitant disease was any clinical illness that required a specific 
and prolonged treatment. In a sample of 113 elderly patients, 68 (60.1%) had a concomitant 
disease that required treatment. Fifteen percent (17/113) of the AML patients had more than one 
comorbidity. Concomitant diseases were arterial hypertension (29 patients), ischemic 
cardiovascular disease (20 patients), diabetes (18 patients), chronic respiratory disease (9 
patients), and chronic gastrointestinal disease (6 patients). The combination of age and 
comorbidities impacted treatment decisions with a palliative approach chosen for 77% of patients 
over 70 years and for 48% of those under 70 years with concomitant diseases (P=0.032). For 
patients without comorbidities, age did not influence treatment decisions. Concomitant illnesses 
were associated with decreased survival, with median survival of 33 weeks (95% CI: 15–52 
weeks), which was significantly shorter than that of patients without concomitant diseases 
(median not reached; P=0.014). However, QOL data were not provided for comorbidities 
because this was not the focus of the study. Rather, the focus was on survival of elderly AML 
patients. Small sample size is a limitation of this study.  
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QOL in Myelodysplastic Syndromes 
The literature has limited research on QOL and AML/high-risk MDS. The majority of 
studies separate QOL evaluation of MDS from AML. Acute myeloid leukemia and MDS are 
bone marrow stem cell disorders that are treated similarly and have a limited life expectancy. 
The review of research begins with QOL in MDS and proceeds to AML QOL research. 
The most recent nursing study on QOL in patients with MDS was qualitative, using a 
phenomenological approach (Thomas, 2012), because limited information was available about 
how MDS affects individuals living with the illness. The sample consisted of 70 patients 
recruited from an Internet posting on the Myelodysplastic Syndrome Foundation website. Five 
focus groups over five months convened in the United States. Individuals with a diagnosis of 
MDS were asked how the diagnosis affected their QOL. All focus group sessions were audio 
taped, transcribed, and coded for common themes. 
Qualitative data from this study suggests that MDS has a substantial and negative impact 
on QOL for patients diagnosed with the disease. However, for the majority of the patients, the 
impact of MDS on physical well-being was minor. The impact of MDS on the functional abilities 
of the participants varied greatly, with some patients noting that they were no longer able to 
perform their normal activities, and other participants not reporting any limitations in their 
functional abilities. A diagnosis of MDS negatively affected emotional well-being, with patients 
voicing significant anxiety concerning the uncertainty of their prognosis and treatments, and 
receiving very limited teaching and emotional support from the health care team. For spiritual 
well-being, the majority reported a positive impact, with a need for reprioritization of values with 
a life limiting illness. Recommendations from the study included a more comprehensive 
approach to the care of MDS patients that includes nursing, behavioral medicine/psychology, and 
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social work. Suggestions were made for further studies to explore the impact of MDS on QOL in 
more detail to target interventions to assist patients coping with a complex, chronic malignancy 
(Thomas, 2012). 
Steensma et al. (2008) conducted a study to quantify the burden of fatigue and other 
disease-associated symptoms in a large group of patients with MDS treated at multiple 
institutions and how they influenced QOL. The sample consisted of 359 patients recruited from 
the MDS Foundation by way of the Internet. The Charlson Comorbidity Index, Brief Fatigue 
Inventory, FACT-Anemia, and the Godin Leisure Time Activity Score measured fatigue, 
comorbidities, functional capacities, and other activities. The instruments were available on the 
Internet from January through October 2006. Patients were asked to complete the questions only 
once. From these surveys, 65% of patients reported having received blood products at some point 
since their MDS diagnosis. Excessive fatigue was the most common symptom (89%) reported by 
patients with MDS. Other problems included bruising/bleeding (55%), night sweats (43%), bone 
pain (39%), fevers (28%), skin rash (25%), undesired weight loss (25%), and recurrent infections 
(20%). Myelodysplastic syndrome impaired patients’ ability to work. Disability due to MDS 
diagnosis was reported at 30%. As expected in this age group, 60% of the patients were 
“retired.” Scores on QOL tools were markedly inferior to the general population. For FACT-
Anemia, MDS patients scored a standardized mean of 50.5, compared to 77.1 for controls (where 
100 is best possible QOL); p < 0.0001. The findings were similar for fatigue measurement. From 
this study, it was clear that patients with MDS experience debilitating fatigue that interferes with 
their ability to work. In addition, many of the patients with MDS were receiving active treatment 
for their MDS, illustrating the inadequacy of therapy in relieving symptoms associated with the 
disease process. It is also difficult to tease apart the symptoms due to treatment versus MDS. 
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Another important finding from this Internet study was the weak correlation between fatigue and 
hemoglobin levels. This study provided evidence that patients with MDS have significant 
symptoms that negatively affect QOL.  
Azacitidine is an active treatment for MDS patients used to improve blood counts and 
prevent disease progression. In a phase III clinical trial, Kornblith et al. (2002) evaluated the 
impact of azacitidine on the QOL of 191 patients with MDS. Patients were randomized to 
receive either azacitidine as a subcutaneous injection seven days every four weeks, or supportive 
care. Crossover was allowed from the supportive care arm to azacitidine arm with disease 
progression. Measurement of QOL was conducted by phone interviews at baseline, and on days 
50, 106, and 182. The EORTC QLQ-C30 and Mental Health Inventory were administered as the 
QOL measure. Patients treated with azacitidine experienced statistically significant 
improvements in fatigue, physical functioning, dyspnea, positive effect, and psychological 
distress. The greatest improvements were in fatigue and psychological state. Also noted was 
disease response, and delayed progression to AML, or death compared to the supportive care 
arm.  
Despite encouraging treatment results, MDS negatively influences QOL of patients, 
according to Thomas (2012). The most common symptom reported by MDS patients is fatigue, 
which is not totally explained by anemia. In addition, as noted by Steensma et al. (2008), there 
are several other symptoms that patients report as negatively influencing QOL. Many symptoms 
are related to bone marrow failure, such as bleeding from thrombocytopenia, and the need for 
frequent transfusions with blood for anemia, and treatment for infections from neutropenia 
(Greenberg, et al. 2011). However, psychosocial factors play a considerable role in QOL for 
MDS patients. According to Thomas (2012), uncertainty concerning the disease and treatment 
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negatively impact QOL with patients reporting receiving limited emotional support and 
education from the healthcare team.  
QOL in AML  
Limited information is available concerning QOL for older AML patients. To date, the 
primary objective of clinical trials has been evaluation of response to treatment, length of 
hospitalization, overall survival, and the biology of the disease. Quality of life has been the 
secondary focus of many clinical trials, utilizing various instruments (Joly, Vardy, Pintilie, & 
Tannock, 2007). Without a uniform definition or tool for measurement for QOL, it is difficult to 
compare results between studies (Grant & Sun 2010). Patients can make more informed 
decisions regarding therapy with QOL data. It is reasonable that if two treatments are equally 
effective in treating AML or MDS, the one that results in a more favorable QOL would be 
chosen.  
 Clinical trials have evaluated various treatments in an attempt to improve overall survival 
in elderly patients with AML (Baron & Storb, 2007; Kantarjan et al. 2006; Sekeres et al., 2004). 
The impact of the various treatments on various conceptualizations of QOL was also assessed 
during these trials. In a prospective, randomized clinical trial by Lowenberg et al. (1989) survival 
was compared between two treatment approaches in 60 AML patients 65 years or older. The first 
treatment approach consisted of giving immediate intensive chemotherapy early in the course of 
the illness, known as arm A. The second treatment approach, arm B, consisted of a “wait and 
see” approach that included best supportive care. Chemotherapy was administered to patients in 
the “wait and see” group if their condition deteriorated rapidly, and treatment was thought 
necessary. The number of days spent in the hospital was used as a surrogate marker for QOL, 
which is not a measurement for QOL. Overall survival duration for patients treated on arm A 
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was significantly (p=0.15) longer than the survival in arm B (21 weeks versus 11 weeks). The 
percentage of days spent in the hospital was 55% in arm A, and 50% in arm B. However, there 
are obvious flaws in the definition and measurement of QOL. In addition, by waiting until the 
patients in the “wait and see” group were more ill, they naturally would be less likely to respond 
to treatment. 
In a prospective, longitudinal study, Sekeres and colleagues (2004) examined the 
decision making considerations and QOL of 43 older adults with AML and advanced MDS in 
choosing between intensive chemotherapy (IC) and non-intensive chemotherapy (NIC). Patients 
were enrolled upon presentation to the participating institutions. Baseline questionnaires were 
completed prior to starting treatment, or within one day of starting IC. For the NIC group, 
questionnaires were completed at baseline and at two and six weeks of enrollment. The FACT 
both general and anemia specific measurements, and a shortened version of the Geriatric 
Depression Scale (GDS) were also administered. The FACT-Anemia is a QOL instrument that 
contains a general section (FACT-G), with four domains assessing physical well-being, 
social/family well-being, emotional well-being, and functional well-being (Cella, 1997). Within 
all measures except the GDS, higher scores indicate a better QOL. Patients choosing IC were 
younger, with a median age of 66 years than those choosing NIC, with a median age of 76 years. 
Baseline QOL scores and prevalence of depression were similar for both groups. Quality of life 
scores significantly deteriorated in the intensive chemotherapy group during the second week for 
the General FACT and Short Form 12 physical scores, which measures perceptions of physical 
functioning and not QOL. For the NIC group, the scores remained stable for QOL. By week 6, 
which correlated with hospital discharge, the IC group, as measured by physical functioning, had 
improved. Mortality rates at six weeks were similar between the two groups (Sekeres et al., 
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2004). By one year, five patients from each group remained alive. In the IC group, QOL physical 
scores were negatively impacted during the time of hospitalization, which correlated with time of 
treatment with IC. This suggests that a less intense, outpatient approach could maintain QOL 
without negatively impacting survival because the survival rates between the two groups were 
similar at one year for this sample. 
Kantarjian et al. (2006) compared treatment with decitabine, a hypomethylating agent, in 
patients with MDS to best supportive care in a phase III randomized control trial. A total of 170 
patients were randomized to receive decitabine every six weeks or best supportive care. 
Following review by an expert pathology group outside the study institution, a portion of the 
MDS patients were reclassified as having AML. The median age of patients was 70 with a range 
from 30-85 years. Quality of life was evaluated using the EORTC QLQ-C30. This instrument 
incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, 
and social), three symptom scales (fatigue, pain, and nausea, and vomiting), and a global health 
and QOL scale, with higher scores correlating with a better QOL. Evaluations were performed 
for QOL at the end of each treatment cycle. When compared to the supportive care group, the 
decitabine arm of treatment demonstrated a statistically significant superior QOL score in global 
health (p<0.05 at the end of cycles two and four), fatigue subscale (p<0.05 at the end of cycles 
two, four, five, and six), and dyspnea subscale (p<0.05 at the end of all six cycles).  
In an observational study by Alibhai et al. (2007), the effect of IC on QOL and functional 
status of 65 elderly AML patients was compared to NIC treatment. The age range for the NIC 
was 66-86 years with a mean age of 76.9 years. The IC group had a similar age range of 61-84 
years with a mean age of 70.4 years. Quality of life and functional status were assessed at 
baseline, one month, four months, and six months in newly diagnosed AML aged 60 years or 
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older. The decision to treat with IC versus NIC was made by the physician based on clinical 
presentation. Quality of life was measured using the EORTC QLQ-C30. The FACT Fatigue 
subscale was used to investigate fatigue. Results for measurements of fatigue were reported in a 
separate manuscript. Quality of life was not inferior in the group that received NIC. 
In a much larger study, Juliusson et al. (2009) retrospectively evaluated 2767 patients 
with AML diagnosed from 1997-2005 through the Swedish Acute Leukemia Registry. Early 
death rates (within 30 days of diagnosis) were lower with intensive treatment despite poor 
performance status at the time of diagnosis. Long-term survivors, not defined by the 
investigators, were found among elderly patients treated with IC. Recommendations were for 
treating elderly AML patients up to 80 with IC. This is contrary to recommendations from 
previous studies and emphasizes the ambiguity in treating older AML patients.  
From an investigation by Oliva et al. (2011), QOL was identified as a prognostic factor 
for survival. In a prospective, observational study, 113 patients greater than 60 with AML 
completed two QOL instruments at diagnosis for all patients. The two instruments utilized were 
the EORTC QLQ C-30 and a health-related QOL questionnaire for patients with hematologic 
diseases (QOL-E). At diagnosis, patients were noted to have decreased general QOL-E (median 
QOL-E standardized score 54, interquartile range 46-70; median EORTC global score 50, 
interquartile range 41-66). The treating physician assigned most patients an Eastern Cooperative 
Oncology Group performance status score, which was favorable. These scores did not correlate 
with the patients’ self-report of QOL. Survival was independently predicted by QOL-E 
functional (P=0.002) and EORTC QLQ-C30 physical function (P=0.030) scores when age and 
comorbidities were factored out. This has practice implications because therapy decisions are 
commonly based on the treating physicians’ assignment of a performance status, as opposed to 
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the patient. From these results, further research should be performed to confirm the findings. 
This provides evidence for the valuable information that can be obtained from QOL assessments. 
Conclusions 
 In summary, this chapter presented a review of the literature related to QOL in older 
patients diagnosed with AML and high risk MDS. The conceptual framework that guided the 
design of the study was introduced as well as the major variables proposed to be predictors of 
QOL for high-risk MDS and AML patients. Age and comorbidities are the primary variables for 
treatment determination in high risk MDS and AML, especially when looking for curative 
therapy with hematopoietic stem cell transplant. Fatigue is the most frequently reported symptom 
in MDS, and identified as a predictor of QOL in previous studies. This needs more close 
examination in AML. Currently, there is a need for better QOL data including predictors so that 
patients can make informed decisions concerning available treatments and their impact on QOL. 
In the next chapter, the design and methods of the study are presented, with a description of the 
instruments utilized to measure QOL, comorbidities, and fatigue. 
 The conceptual model that guided this study (Figure 1) symbolizes the effects of age, 
diagnosis, comorbidity, and fatigue on QOL, and the moderating effect of treatment on QOL. 
The variables on the left of the model guide treatment decisions, and were chosen for their 
logical association with QOL. A comparison of QOL between treatment approaches appears on 
the right side of the model.  
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Figure 1: Conceptual Model for the Study 
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CHAPTER THREE: 
METHODS 
 In this chapter, the methods for the study are presented. This includes the design of the 
proposed study, sample, setting, data collection, measures, and plan for data analysis. The 
process for protecting human subjects is described.  
Study Design 
 The study utilized an exploratory observational, longitudinal cohort design comparing 
QOL between two treatment approaches in patients 60 years of age and older with high-risk 
MDS and AML at two time points. The plan was to compare three treatment groups, but low 
accrual for the supportive care group restricted evaluation to two groups. A randomized 
controlled trial was not possible because physicians base treatment decisions on prognostic 
indicators and patient preference. In addition, there would be ethical concerns for randomization 
to specific treatment versus supportive care given the diagnosis of the participants. 
Setting 
 The setting for the study was Moffitt Cancer Center and Research Institute in the 
department of Malignant Hematology. Moffitt is a National Cancer Institute designated 
Comprehensive Cancer Center that sees more than 100 new leukemia and high-risk MDS 
patients annually. The collection of data occurred in both outpatient and inpatient setting. 
Sample 
Recruitment of 85 patients with high-risk MDS and AML occurred at the time of 
appointments in the Hematology Clinic or during admission to Moffitt Cancer Center for 
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treatment evaluation of AML or high-risk MDS. This number of participants was based on 
power analysis. A sample size of 100 was suggested for five predictors with an effect size of .14, 
and an alpha of .05, with 80% power. Inclusion criteria include individuals 60 years of age and 
older with confirmed diagnosis of high-risk MDS or AML based on bone marrow pathology 
reports. High-risk MDS and AML were treated as one group. Patients were able to read, write, 
and speak English, were oriented to person, place, and time, and were willing to participate.   
Measures 
 FACT-Leukemia  
Quality of life was assessed at the time of enrollment and within at least one month of 
enrollment using the FACT-Leu. The domains included in the FACT-Leu are social/family well-
being, physical well-being, functional well-being, and relationship with their physician (Cella, 
Tulsky, & Sarafian, 1993). The instrument consists of 28 Likert-type items, with patients asked 
to respond to each item with a score of zero to four, with zero indicating “not at all” and four 
meaning “very much.” Scores range from zero to 112 with higher scores indicating better QOL. 
A subscale specific for leukemia is added to the general scale. The leukemia subscale consists of 
17 items, with a score range of zero to 68. Evidence for convergent validity of the general 
instrument was provided by Cella et al. (1993) based on data from 854 patients with various 
cancer diagnoses when compared with the Functional Living Index-Cancer (FLIC), with a 
Pearson product moment correlation of 0.79. Victorson, Barocas, Song and Cella (2008) 
provided evidence of reliability in a study where 344 publications were reviewed based on 
predetermined criteria. Seventy-eight published studies reported Cronbach’s alpha reliability 
coefficients. They found the FACT-General score reliability to be .88 with a range of subscales 
from .71 to .83.  
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Brief Fatigue Inventory 
Fatigue was measured using the Brief Fatigue Inventory (Mendoza, Wang et al. 1999) at 
the time of enrollment in the study. This is a one page, nine-item questionnaire, which measures 
fatigue on a scale of zero to ten, with zero indicating no fatigue, and ten representing the worst 
fatigue that a person can imagine. This instrument has been used in acute and chronic leukemia 
(Chang et al., 2008; Shanafelt et al., 2007). There is evidence of construct validity of the 
instrument by factor analysis. Evidence of concurrent validity of the instrument was 
demonstrated by correlating the Brief Fatigue Inventory with other fatigue measures such as 
Profile of Mood States. Cronbach’s alpha coefficient for internal consistency reliability was very 
high (alpha =0.95 and 0.96) (Mendoza, Wang et al., 1999). 
 Charlson Comorbidity Index 
Measurement of number of comorbidities was performed at the time of enrollment using 
the Charlson comorbidity index (Charlson, Pompei, Ales, & MacKenzie, 1987). The electronic 
version of the tool was utilized (Charlson, Szatrowski, Peterson, & Gold, 1994). This tool was 
developed to assign a number that estimates risk of mortality related to number and severity of 
comorbidities. It is the most commonly used instrument for evaluation of comorbidities in 
elderly patients with hematologic malignancies (Extermann, &Wedding, 2011). The index 
encompasses 19 medical conditions weighted one to six with total scores ranging from 1to 37. A 
single score, which is a sum of the weighted conditions, is tallied. There is evidence of reliability 
of the instrument with inter-rater reliability, reported at 0.74 among a cohort of older general 
oncology patients and 0.945 within a group of elderly breast cancer patients (Extermann, 2000). 
Test-retest reliability was also excellent, ranging from 0.92 among surgical patients and 0.86 
among the previously mentioned group of elderly oncology patients.  
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  Demographic Data 
Baseline information obtained on all subjects included age, as measured by date of birth, 
and diagnosis from pathology report including chromosome analysis by G-banding technique, 
and by fluorescence in situ hybridization. Demographic data collected also included gender, 
marital status, level of education, income level, religious ceremony attendance on a scale of zero 
to four, and designation of intensive, non-intensive, or supportive care treatment.  
Procedures 
 Approval was obtained from the Scientific Review Committee (SRC) at Moffitt followed 
by approval from the Institutional Review Board (IRB) of the University of South Florida. 
Patients were approached by the principal investigator at their scheduled appointment or during 
the first week of their admission to obtain the informed consent, and administer the 
questionnaires. Eligibility was confirmed by utilization of a checklist. A quiet, comfortable room 
was provided for completing the questionnaires. A copy of the consent form was provided to 
participants to keep for future reference, and contact information was within the consent form. It 
was emphasized that participation was voluntary, and their care would not be altered, regardless 
of study participation. Demographic data collection was captured using a two-page sheet 
completed by each patient. The FACT-Leu and Brief Fatigue Inventory were administered 
within the first week of treatment. The second FACT-Leu was administered at least four weeks 
later. Data was stored in a locked filing cabinet in a locked office in the Hematology Clinic. All 
data was extrapolated to Excel spreadsheets coded only by patient identification number to 
ensure patient confidentiality. A patient identification number was assigned to each subject to 
assure confidentiality. The FACT-Leu scores were designated as FACT-Leu 1 and FACT-Leu 2 
to identify first and second measurement. 
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Data Analysis 
 Data was analyzed using Statistical Package for the Social Sciences version 22 for 
Windows (IBM, Armonk, NY). Data was screened for outliers, and missing data. Descriptive 
statistics was used to describe study participants and study variables. Level of significance was 
set at an alpha level of .05. The following aims were addressed and data synthesized for 
conclusions. 
 Aim One: QOL from Week 1 to Week 4 
 To compare the difference in QOL scores measured by the FACT-Leu for intensive 
chemotherapy, non-intensive therapy, and supportive care within 7 days of new treatment and 
one month after initiation of treatment in older adults with AML or high-risk MDS. Repeated 
measures analysis of variance was ran as group, time, and group by time, with follow up tests for 
significant findings for the interaction. The groups included intensive versus non-intensive and 
supportive care. Time was the first and second measurements of FACT-Leu. 
 Aim Two: Predictors of QOL 
 To determine QOL predictors of AML and high risk MDS from age, comorbidity, 
fatigue, and diagnosis. Bivariate correlations were analyzed between age, Charlson Comorbidity 
Index, Global Fatigue Score, and FACT-Leu, time 1. Diagnosis, as a categorical variable, was 
recoded as a dummy variable and contrasted all groups with high risk MDS.  
 Aim Three: Moderators of QOL 
 To test the moderating effect of treatment with age, comorbidity, and fatigue on QOL. 
Linear regression was performed to determine the moderating effect of treatment on age, 
comorbidity, and fatigue on the second QOL score. 
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CHAPTER FOUR: 
 RESULTS 
 The results of the study are provided in this chapter. Descriptive statistics of the sample 
are presented, separated by treatment group allocation. This is followed by means and standard 
deviations of all instruments with study totals divided by treatment group. Finally, the three aims 
of the study are statistically analyzed with tabled results and explanation. 
Sample 
 The sample was comprised of 85 subjects recruited from the Malignant Hematology 
Program at Moffitt Cancer Center. The suggested sample size was not achieved due to slow 
accrual with one investigator, and time sensitive enrollment; within one week of treatment. 
Statistically significant findings were obtained with the sample of 85. All participants had a 
confirmed pathologic diagnosis of AML or high risk MDS. The sample was predominantly 
white, male, retired, middle class, and attended religious activities at least twice per month 
(Table 1).  
  Demographic data was divided by treatment groups to determine if the groups varied 
demographically. The intense treatment group had slightly more women than the non –intense 
and supportive care groups (Table 1). The supportive care group was comprised of five women, 
with varying ethnic backgrounds, and included no men. There were approximately equal 
numbers of participants at the lowest level and highest level of income reported. The majority of 
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participants reported income between $25,000 and $99,000 annually. Most (73%) were retired 
(Table 1).  
 
Table 1. Frequencies and Percentages of Demographic Variables. 
 Intense (n=46) Non-intense (n=34) Supportive care (n=5) Total (n=85) 
Variable Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
Male 29 63 27 80 0 0 56 66 
White 44 96 33 97 3 60 80 94 
Married 30 65 26 77 5 100 61 72 
Retired 31 67 28 82 4 80 63 74 
Middle class 27 59 20 59 3 60 50 60 
High school education 20 44 17 50 2 40 39 46 
College education 20 44 16 36 3 60 40 47 
Monthly religious activity 23 50 14 41 3 60 40 47 
 
The age of the sample was constrained to patients 60 years of age and older. Among the 
three groups, the mean age was slightly lower for the induction group by four years; however, 
the range was similar (Table 2), ranging from the sixties to the 80’s. Each treatment group had 
patients in the lower and higher ages. 
 
Table 2. Mean, Range, and Standard Deviation of Age for Groups. 
Age Intense Non-intense Supportive Care Total 
Mean 70 74 74 72 
Range 61-83 60-88 63-86 60-88 
Standard deviation 6.18 6.97 8.56 6.85 
 
Categorical variables and age were analyzed between the intense and non-intense groups, 
using Chi-square and paired t-test for age. The groups were not significantly different from each 
other. Supportive care was not included because of low accrual (Table 3).  
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Table 3. Chi Square and Paired t-Test for Demographic Variables Between Intense and Non-Intense Treatment for Subjects Who 
Completed Both QOL Measures (N=67). 
 
Variable 
 
Chi square t df p 
Age  - 1.972 65 .580 
Gender 2.288 - 1 .130 
Ethnicity 2.847 - 3 .416 
Marital status 7.255 - 4 .123 
Employment 2.756 - 5 .738 
Income 2.638 - 3 .451 
Education level 7.261 - 8 .509 
Religious activity 3.975 - 5 .553 
 
Diagnosis varied between the three treatment groups. Five categories of diagnosis were 
coded with results reported (Table 4). Participants with AML were treated with both intense and 
non-intense treatment. A higher percentage (24%) of patients with high risk MDS were treated 
with a non-intense therapy, and supportive care (40%). Four different diagnosis categories were 
among the supportive care group. Patients with AML received all three types of treatments. The 
highest accruing groups were AML with MDs changes (37%) and AML (34%). 
 
Table 4. Frequencies of Diagnoses. 
Diagnosis Intense (n=46) Non-intense (n=34) Supportive Care (n=5) Total (n=85) 
AML 16 12 1 29 
AML with MDS changes 23 8 - 31 
AML-therapy related  3 2 - 5 
AML from MPN* 2 1 1 4 
MDS- High risk 2 8 2 12 
MDS- therapy related  - 3 1 4 
*MPN-Myeloproliferative neoplasm 
  
The three instruments used in this study were the Charlson Comorbidity Index, the Brief Fatigue 
Inventory, and the FACT-Leu. Results for the means and standard deviations of the three 
instruments, separated by treatment group are reported in Table 5.  
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 Table 5. Means and Standard Deviations of Instruments    
Variable  Intense 
(n=46) 
Non-intense 
(n=34) 
Supportive care  
(n=5) 
Mean Total 
(n=85) 
   
CCI a*  1.15 ± 1.28 1.56 ± 1.70 0.6 ± .89 1.28 ± 1.45    
GFS b*  4.34 ± 2.52 4.23 ± 2.21 5.92 ± 2.09 4.39 ± 2.39    
FL1 c*  117.53 ± 24.01 116.36 ± 27.45  106.37 ± 12.15 116.41 ± 25.00    
FL2 d*  126.06 ± 22.60  (n=41) 113.76 ± 24.70 (n=26) 108.50 ± 6.35 (n=4) 120.64 ± 23.54 (n=72)    
 a*- Charlson Comorbidity Index, b*-Global Fatigue Score c*- FACT-Leu 1, d* -FACT-Leu 2 
 
Descriptive Data 
Aim One: QOL from Week 1 to Week 4  
 The comparison between two groups, intense and non-intense treatment is presented in 
Table 6 on FACT-Leu scores taken at two time points. The supportive care group was not 
included in the analysis because of low accrual. Repeated measures analysis of variance was 
utilized to determine main effects of time, group, and group by time interaction. An interaction 
of group by time was statistically significant (p = .040).  
 
Table 6. Repeated Measures Analysis of Variance of Group, Time, and Group by Time (N=67) for QOL Scores. 
Effect MS df F p 
Time 147.107 1 .449 .505 
Group 654.160 1 1.477 .229 
Group x Time 1491.211 1 4.555 .040 
 
Follow up tests were performed to determine the effect of time for each of the treatment 
groups. The results are reported in Table 7. There was a significant improvement in QOL scores 
between the first and second measurement in the induction group (p=.020). 
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Table 7. Repeated Measures Analysis of Variance for Time by Groups. 
Effect MS df F p 
Intense treatment 1634.17 1 5.76 .020* 
Non-intense treatment 317.54 1 0.773 .388 
*Significant at .05 level 
 
Aim Two: Predictors of QOL 
This indicates that as the level of fatigue increased, QOL scores decreased (Table 8).  
 
Table 8. Correlation of Predictors with QOL from FACT-Leu 1 (N=85). 
Variable 
r P 
Age 
.13 0.12 
Charlson Comorbidity Index 
.04 0.35 
Global Fatigue Score 
-.69 < 0.001 
 
Diagnosis is a categorical variable with six levels that were recoded as dummy variables. 
Each diagnosis was contrasted with high-risk MDS (not therapy related) and was correlated with 
QOL (Table 9). Diagnosis was not significantly correlated with QOL. 
 
Table 9. Correlation of Diagnosis with QOL from FACT-Leu 1 (N=85). 
Variable r P 
AML .141 .100 
AML from MDS -.023 .418 
AML Therapy Related .120 .137 
AML from Myeloproliferative Neoplasm -.116 .145 
Therapy Related MDS -.034 .378 
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Regression analysis was performed to determine if the second measure of QOL could be 
predicted from the first QOL score, and then age, comorbidity, and fatigue were entered into the 
model (Table 10). Scores from the FACT-Leu 1 were a significant predictor of the second QOL 
measure (P< 0.001), which explained 19.6% of the variance. With the addition of age, 
comorbidity, and fatigue, the variance explained increased to 22.6%, but was not statistically 
significant. 
 
Table 10. Regression of Predictor Variables on QOL on FACT-Leu 2. 
 
Variable B Standard error of B Beta t P 
FACT LEU1 .422 .106 .433 3.99 < 0.001 
Age  -.666 .434 -.185 -1.533 .130 
Comorbidity .790 1.834 .051 .431 .668 
Global Fatigue -.054 1.532 -.005 -.035 .972 
 
 
Aim Three: Moderators of QOL 
Linear regression was performed with a plug in application by Hayes (2013) to determine 
the moderating effect of treatment with age, co-morbidity, and fatigue on QOL. In Table 11, the 
moderating effects of age with type of treatment analysis are displayed. The results were 
statistically significant, indicating that when combining all three variables, the model predicts 
QOL (p=0.049). 
 
Table 11. Linear regression FACT-Leu 2 from Moderator, Type of Treatment, and Age. 
Model  df Mean Square F p 
1 Regression  3   538.95 2.764 .049b 
      
a. Dependent Variable: Time 2 FACT-Leu Total 
b. Predictors: Moderator, type of treatment, age 
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The coefficients for type of treatment, age, and moderator effect are reported in Table 12. 
The moderator was not significant (p=.066). Type of treatment was significant (p=.043). This 
indicates the main effects of treatment on QOL scores, which was previously shown in Aim One. 
The intensive treatment group had an improvement in FACT-Leu 2 scores. 
 
Table 12. Coefficientsa for Type of Treatment, Age, and Moderator Effects on QOL. 
 
Model 
Unstandardized Coefficients  
t p B Std. Error  
1 (Constant) 307.995 95.659  3.219 .002 
Age -2.376 1.350  -1.760 .083 
Type of treatment -130.960 63.411  -2.065 .043 
Moderator 1.657 .882  1.872 .066 
a. Dependent Variable: Time 2 FACT-Leu 
 
 Multiple linear regression was performed to determine if the second measure of the 
FACT Leu could be predicted from the type of treatment, Charlson Comorbidity Index, and the 
moderator. Results indicated that the score from the second QOL measure could not be predicted 
from the moderator variable (p = .140). 
 Regression was performed to determine if the type of treatment and fatigue with the 
moderator were significant predictors of the FACT-Leu 2. All three combined revealed a 
significant F ratio of 0.12 shown in Table 13. The coefficients in Table 14 indicate that the 
moderator variable was not significant (p=.729). The main effect of treatment was statistically 
significant (p= .016) and the main effect of fatigue was significant (p = .014) shown in Table 14. 
These results are consistent with prior results, which indicate the main effects of fatigue and 
treatment for predicting QOL scores. 
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Table 13. Regression of FACT-Leu 2 from Moderator, Type of Treatment, and Fatigue. 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 6231.364 3 2077.121 3.981 .012b 
      
a. Dependent Variable: Time 2 FACT-Leu  
b. Predictors: (Constant), Fatigue-moderator, type of treatment, Global Fatigue Score 
 
Table 14. Coefficientsa for Type of treatment, Fatigue, and Moderator. 
Model Unstandardized Coefficients Standardized Coefficients t p 
B Std. Error Beta 
1 (Constant) 154.792 10.179  15.207 .000 
Type of treatment -14.477 5.831 -.291 -2.483 .016 
Global fatigue  -3.189 1.267 -.297 -2.517 .014 
Fatigue-moderator -1.042 2.992 -.041 -.348 .729 
a. Dependent Variable: Time 2 FACT-Leu total 
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CHAPTER FIVE: 
 DISCUSSION, IMPLICATIONS AND CONCLUSIONS 
  In this final chapter, the research results are synthesized with discussion of the findings 
from earlier studies. The purpose of this observational longitudinal cohort study was to assess 
how different treatment approaches influence QOL. The study also evaluated predictors of QOL 
for older patients with high-risk MDS and AML who are 60 years of age and older. Quality of 
life was measured using the FACT-Leu at two times points, before and one month following 
treatment. The sample from which the data were obtained is examined, along with descriptive 
statistics of the instruments. The findings for each aim are interpreted and potential explanations 
provided for the results to address the issue of how treatment impacts QOL for patients with 
high-risk MDS and AML. This is followed by implications, conclusions, and recommendations 
for future studies. 
Sample 
 There were 85 subjects with a diagnosis of high-risk MDS or AML who were 60 years of 
age or older. This may have created a restricted range problem in the analysis. However, the 
majority of patients with these diagnoses are 60 years of age and older. This was a 
predominantly retired white male sample, with a medium level of income. Among the three 
groups, the range of ages was similar, with patients from the seventh and eighth decade 
represented in all three groups. Within the sample, there were six levels of diagnoses captured, 
with the most frequently occurring diagnoses being AML without prior bone marrow disorder 
and AML with MDS changes, which is consistent with what is reported in the literature 
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(Applebaum et al., 2006). Prior MDS is also one of the reasons that AML in the older population 
is difficult to treat when compared to AML in patients less than 60 years of age (Stone, 2002).  
 The sample for supportive care was too small to be included in the statistical analysis. 
One explanation for this problem is that Moffitt Cancer Center is a referral center for patients 
seeking treatment. Individuals who only want supportive care are not referred to Moffitt Cancer 
Center. More research is needed to evaluate QOL for patients only receiving supportive care.  
Descriptive Data 
 Three instruments were used in the study to measure comorbidities, fatigue, and QOL. 
Treatment decisions are determined by the physician and patient based on comorbidities, and 
level of functioning at the time of evaluation for determination of treatment. Comorbidities for 
this study were measured using an online calculator for the Charlson Comorbidity Index. An 
unexpected finding was how similar the scores were for the Charlson Comorbidity Index across 
the three groups. Among the three groups, the comorbidity mean scores were 1.2 for intense 
treatment, and 1.6 for non-intense treatment. The lowest comorbidity score was in the supportive 
care group, at 0.6. This was contrary to prior research. Oliva et al. (2011) reported that a 
combination of age and comorbidities impacted treatment decisions with a palliative approach 
chosen for 77% of patients over 70 years, and for 48% of those under 70 years with concomitant 
diseases (P=0.032). A reason for the difference may be the instruments that were used to 
measure comorbidities. Comorbidity was defined as any clinical illness that required a specific 
and prolonged treatment.  
 Fatigue was measured using the Brief Fatigue Inventory, which gives a zero to 10 score. 
The Global Fatigue Scores were similar between the intensive and non-intensive groups, 4.3 and 
4.2 respectively. The supportive care group had the highest GFS at 5.9, indicating that fatigue 
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was greater in the supportive care group, despite fewer comorbidities. Fatigue is poorly 
understood in MDS and AML; however, it is known to be one of the most debilitating symptoms 
reported in the literature, and negatively influences QOL (Meyers, et al., 2005). This may be due 
to limitations in normal activities due to overwhelming fatigue.   
 The focus of this study, QOL, was measured using the FACT-Leu. Each patient 
completed the 3-page questionnaire within the first week of starting treatment (FACT-Leu 1), 
and again at least one month following the first measurement (FACT-Leu 2). From FACT-Leu 1 
to FACT-Leu 2 mean scores improved for the intense chemotherapy (mean =117.5 to 126.1). For 
the non-intense therapy the mean scores decreased (mean= 116.4 to 114.0), an unanticipated 
finding because patients were able to stay home with their families, as opposed to a one-month 
hospitalization. Next, the supportive care group, based on only four patients who completed both 
measures, improved from 106.4 to 108.5. Overall, the first measurement of QOL was similar 
between the induction and outpatient based treatment. However, the mean QOL score for the 
supportive care arm was lower by 10 points, and did not improve to meet the starting mean score 
for the induction or outpatient group by the second measure. Possible explanations for this result 
are discussed in the next section. 
Aim One: QOL from week 1 to week 4 
A comparison was made between two treatment approaches, intensive and non-intensive 
therapy. Supportive care was not included in the analysis because of low accrual with only four 
patients completing both measurements of QOL at two time points. Group by time repeated 
measures analysis of variance was used to compute the results in SPSS version 22. For the main 
effects of group and time, there was not a significant finding. The interaction of group by time 
was statistically significant (p=.040). Then to determine which group by time was significant, 
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follow up tests were performed of the intensive and non-intensive treatment groups. The 
intensive treatment by time was significant (p = .020), and the non-intensive treatment by time 
analysis was not statistically significant.  
 It was an unexpected finding that the most intense treatment, requiring a one-month 
hospitalization separated from the familiar comforts of home showed a statistically significant 
improvement in QOL at one month, while the non-hospitalized group did not. Subscale analysis 
was not performed to determine which areas of QOL were improved the most. The findings for 
the longitudinal inpatient, intensive chemotherapy treatment are new, and have not previously 
been documented. Sekeres (2004) compared intensive chemotherapy with non-intensive 
treatment approaches in 43 patients with AML, finding that QOL declined for the intensive 
chemotherapy group measure by the General FACT and Short Form 12 physical scores at week 
2, but repeat measures for week 4 were not reported by these investigators. The time of 
measurement at 2 weeks is a disadvantage because it is when patients have the lowest blood 
counts, and symptoms may improve as the effects of the treatment abate with time. Thus, the 
difference in time of data collection for the current study likely accounts for the differences in 
results.  
The subjects in the non-intensive treatment group did not change significantly in their 
QOL scores. Rather, they maintained their QOL. When previous comparisons were made 
between non–intense treatment and palliative care by Kornblith et al. (2002), patients who 
received outpatient based hypomethylating azacitidine had a statistically significant 
improvement in QOL. The measurement intervals were different compared to the current study, 
and was not compared to intensive treatment. Instead, the comparison arm was palliative care. 
The current study was limited by low accrual of patients receiving supportive care only.  
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Aim Two: Predictors of QOL 
 Regression analysis was performed to determine if age, co-morbidity, fatigue, or 
diagnosis helped predict QOL scores. For the first regression, 85 patients’ results for the FACT-
Leu 1 were entered, and regression was performed. The FACT-Leu 1 was a significant predictor 
of the FACT-Leu 2 score as might be expected (p<.001). Cancer diagnosis was not correlated 
with QOL score and was left out of the regression; this supported the idea of combining MDS 
and AML patients for this study. Next age, co-morbidity and fatigue were added to see if they 
significantly predicted QOL scores on the FACT-Leu 1. The best predictor of FACT-Leu 2 was 
FACT-Leu 1. Age, comorbidity, and fatigue were not statistically significant. This could be 
attributed to the lack of variance in age, Charlson Comorbidity Index, and the Global Fatigue 
Score. 
Age and comorbidities were not helpful as far as determining QOL with various 
treatments. This could be related to the restricted range of ages, based on the purpose of the 
study, which limits variance in age by study design. In addition, the Charlson Comorbidity Index 
did not discriminate between subjects with symptomatic disease, and those with indolent 
comorbidities. Most patients had similar scores on the index, which did not allow for teasing 
apart the patients who were sicker from comorbid conditions to be able to predict QOL scores. 
Aim Three: Moderators of QOL  
 Moderation of the variables was evaluated by performing regression analysis with a plug-
in program by Hayes (2013). Each moderator was entered into a regression analysis with FACT-
Leu 2 as the dependent variable. There was not a moderator effect of age with treatment (p value 
= .066). The main effect of treatment was significant (p=.043).  
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 Comorbidity and the moderator of comorbidity with type of treatment was not a 
statistically significant predictor of QOL. Many treatment decisions are made based on the 
number and severity of comorbidities. In this study, comorbidities did not correlate with QOL 
scores, and did not help predict how treatment affected QOL. 
 The final moderator effect analyzed was fatigue with type of treatment. When checked 
individually with coefficients, the moderator effect was not statistically significant, but the 
individual variables, both the type of treatment and fatigue score were significant (p= 0.016 and 
p=0.014). This reinforces previous findings that fatigue and type of treatment can predict QOL 
score (Alibhai, Leach, Kowgier, et al., 2007). Schumacher and colleagues (2002) found that 
fatigue was more closely associated with QOL than nausea and vomiting and lack of appetite 
with intensive chemotherapy. Fatigue, identified in this earlier study of 37 patients, was the most 
common symptom that occurred at baseline with all patients, and improved following treatment. 
This would suggest that fatigue is related to the disease process, and when the disease is treated 
QOL can be improved. Other less obvious factors may be involved, such as ongoing support and 
encouragement of the healthcare providers throughout the inpatient hospitalization, which may 
improve the emotional and physical health of the patient.  
 The results of this study have identified new findings about QOL and treatment in 
patients with AML and high-risk MDS. This is the first study which has shown that QOL of 
patients 60 years of age and older have a statistically significant improvement in QOL one month 
after completing intensive chemotherapy treatment. This measurement is taken at the end of a 
prolonged hospitalization, away from their normal routine and home. Improvement in QOL was 
not an anticipated finding, and may represent some underlying process that is not obvious, such 
as hope after completing treatment. Many patients fear dying, and may be relieved that they 
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survived the treatment long enough to return home. It may also reflect improvement in QOL that 
is relative to how inferior QOL was prior to treatment. Data was not obtained with regards to 
treatment response. This would be an important addition to future studies that evaluate QOL with 
various treatment approaches.  
 Another explanation for the improvement in QOL scores is the potential improvement in 
disease related symptoms, which are more immediate with intensive treatment. In contrast, less 
intensive, outpatient based therapy works over time, and at the end of only one month of 
treatment, disease modifying benefits have not yet been achieved. This may explain why the 
outpatient group had an overall stable QOL score. Conclusions cannot be drawn from the 
supportive care group, and low accrual is related to the setting for the study, a comprehensive 
cancer center. Patients who seek care at comprehensive cancer centers are usually interested in 
pursuing active therapy. If a comparison is to be made with supportive care, and alternative 
setting should be pursued, such as hospice, or a community cancer center.    
Implications for Nursing 
 Fatigue was highly correlated with QOL score, and the information was easily obtained 
from a one-sheet questionnaire, which took approximately 3-5 minutes to complete. This is the 
focus for many patients, and should be routinely evaluated in clinical settings. Interventions can 
be tailored to improve aspects of fatigue that are not directly related to the disease, such as 
hydration and sleep patterns disrupted by worry.  
 The results of this study will be submitted for publication in the Oncology Nursing 
Forum. The results can be included in education of nurses for fatigue assessment and 
management. The NCCN guidelines include a section on cancer related fatigue that can be 
utilized for curriculum development for fatigue management in oncology patients. Nurses are in 
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a key position for educating and encouraging patients in management of fatigue to improve 
QOL. 
Implications for Future Research 
 Nurse researchers can design future studies to focus on fatigue interventions, and 
systematically evaluate the responses. This could make an impact on QOL by targeting fatigue.  
In addition, a future study is needed that includes the supportive care group. Accrual was limited 
by the setting of the current study, which could be expanded to include community cancer 
centers and hospices. This study is limited by the predominantly white male sample. Additional 
studies should include a more diverse ethnic background, which includes equal representation of 
participants that exemplify the type of AML and high-risk MDS patients in the United States. In 
addition, the non-intense treatment group was limited by inclusion of patients who were treated 
on clinical trials, as well as with hypomethylating agents. The experiences of these patients may 
have varied, and the current study was not designed to separate the subgroups within the non-
intense treatment group. An alternative research design suggestion is the limitation of the non-
intense group to hypomethylating treatment, such as decitabine and azacitidine. Additional QOL 
measurements at three months, and six months would provide information about how QOL 
changes with time. For the non-intense treatment group, an expectation would be that their QOL 
would improve if additional measures were taken. 
Study Limitations 
 The primary limitation of this study is sample size and composition. With larger 
numbers, there may have been moderating effects of treatment with age, comorbidity, and 
fatigue. In addition, this predominantly white, male group limits the generalizability of the 
findings. The supportive care group was small, with only five patients. Most patients seeking 
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care at a comprehensive cancer center are interested in pursuing active therapy instead of 
supportive care. This also limits the findings to other comprehensive cancer centers. The patient 
experience may differ in a community setting.  
Conclusions 
 In conclusion, this study revealed that QOL was improved at one month for patients with 
AML or high-risk MDS who were treated with intense chemotherapy. For patients who were 
treated with non-intense therapy, QOL was stable at one month. Fatigue was identified as highly 
correlated with QOL, and is a predictor of QOL. Fatigue management is a recommended focus 
for future intervention studies. The significant predictor of the second QOL measure was the first 
QOL measure. Age, comorbidity, and fatigue with type of treatment failed to show a moderating 
effect on QOL. Future studies with larger numbers are recommended to confirm the findings and 
provide additional clinical information to help patients choose the treatment approach that 
matches their individual goals.  
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Appendix A: Institutional Review Board Approval 
 
RESEARCH INTEGRITY AND COMPLIANCE 
Institutional Review Boards, FWA No. 00001669 
12901 Bruce B. Downs Blvd.. MDC035 • Tampa. FL 35612-4799 
UNIVERSITY OF (813)974-5638 • FAX (SI 3) 974-7091 
SOUTH FLORIDA 
December 18, 2013 
Sara Tinsley, ARNP 
H Lee Moffitt Cancer Center  
Tampa, FL 33612 
RE: Expedited Approval for Initial Review 
IRB#: ProOOOI4329 
Title: Predictors of Quality of Life in Patients with AML and high 
risk MDS 
Study Approval Period: 12/18/2013 to 12/18/2014 
Dear Ms. Tinsley: 
On 12/18/2013, the Institutional Review Board (IRB) reviewed and APPROVED the above 
application and all documents outlined below.  
Approved Item(s): 
Protocol Document(s): 
17606 2013.09.16 Revised protV2 clean 
Consent/Assent Document(s)*: 
14329 12-01-2QI3.doc Version I informed consent.pdf  
*Please use only the official IRB stamped informed consent/assent document(s) found under the 
"Attachments" tab. Please note, these consent/assent document(s) are only valid during the approval perio d 
indicated at the top of the form(s).  
It was the determination of the IRB that your study qualified for expedited review which includes activities 
that (1) present no more than minimal risk to human subjects, and (2) involve only procedures listed in one or 
more of the categories outlined below. The IRB may review research through the expedited review procedure 
authorized by 45CFR46.110 and 21 CFR 56.110. The research proposed in this study is categorized under the 
following expedited review category:  
(7) Research on individual or group characteristics or behavior (including, but not limited to,  
  
58 
 
 
research on perception, cognition, motivation, identity, language, communication, cultural beliefs or 
practices, and social behavior) or research employing survey, interview, oral history, focus group, 
program evaluation, human factors evaluation, or quality assurance methodologies. 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval by an amendment. 
We appreciate your dedication to the ethical conduct of human subject research at the University of 
South Florida and your continued commitment to human research protections. If you have any 
questions regarding this matter, please call 813-974-5638. 
Sincerely, 
 
Kristen Salomon, Ph.D., Vice Chairperson 
USF Institutional Review Board 
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Appendix B: Scientific Review Committee Approval 
 
 
October 11, 2013 
Sara Tinsley 
H. Lee Moffitt Cancer Center & Research Institute 12902 Magnolia Drive Tampa, FL 
33612 
Dear Ms. Tinsley: 
RE: MCC 17606 “Predictors of Quality of Life for High Risk MDS and AML Patients” 
The Behavioral Subcommittee of the Scientific Review Committee (SRC) has reviewed your response 
dated 09/28/2013 for your research protocol. The revised protocol version 2 dated 09/16/2013 is 
approved as written for use at the Moffitt Cancer Center pending approval of the Institutional Review 
Board (IRB) and satisfaction of institutional operational and financial review requirements. 
Please be aware that after you receive IRB approval, you must request study activation before you 
commence any study activities. Please contact PSO mailbox at PSQmailbox@moffitt.ora to request 
study activation. That office will ensure that all applicable institutional reviews have been completed. 
You will then be issued an automated activation notification by email. 
It is your responsibility to ensure that all Moffitt staff (nursing, pharmacy, data management, etc.) are 
informed and aware of the details of the project. The committee encourages the use of inservices for 
those projects that are complex or require special attention. 
All changes made to protocols approved by the SRC must be submitted to the Protocol Review and 
Monitoring System office. Changes made to the protocol document require SRC review and approval. 
Minor changes (i.e. changes to personnel, non-scientific changes, changes that do not affect patient 
participation) will be expedited through the SRC review process. 
If this project is not being managed by the Clinical Trials Office or Clinical Research Unit, then it is your 
responsibility to follow through with all requirements for submission to the IRB. All IRB approvals are 
required to be documented in Oncore, and all associated regulatory documentation (signed 
applications, IRB approval letters and IRB approved consent forms, etc.) are to be saved in the 
appropriate study folder in the e-binders directory at J:\ebinders. 
Oncore is the Cancer Center’s mechanism for submission and review of materials requiring Scientific 
Review (SRC) and Protocol Monitoring (PMC). If you need access to Oncore, please contact Jeryl 
Madden, Oncore Administrator, at 745-6964 for assistance. 
Sincerely, 
 
David Drobes, PhD. 
Chair, Behavioral Sub-Committee Scientific Review Committee 
MOFFITT 
C A N C E R  C E N T E R  
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Appendix C: Charlson Comorbidity Index 
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Appendix D: Terms and Conditions for Use of Charlson Comorbidity Index  
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Appendix E: Demographic Questionnaire 
 
DEMOGRAPHIC QUESTIONS 
 
What is your month and year of birth? (MM/YYYY) 
 
What is your gender? 
o  Male  
o  Female 
 
Would you describe yourself as: 
o  American Indian / Native American o Asian 
o  Black / African American o Hispanic / Latino  
o  White / Caucasian  
o  Pacific Islander  
o  Other 
 
Marital status 
o  Married  
o  Divorced  
o  Widowed  
o  Separated  
o  Never been married  
o  A member of an unmarried couple 
 
How many children live in your household who are: 
o  Less than 5 years old?  
o  5 through 12 years old?  
o  13 through 17 years old? 
 
How would you describe your current employment status? 
o  Employed full time  
o  Employed part time  
o  Unemployed / Looking for work 
o  Student 
o  Homemaker 
o  Retired 
o  Unable to work 
 
What do you expect your family income from all sources before taxes to be? 
o  Under $24,999 
o  $25,000 - $99,999 
o  Over $100,000 
 
What is the highest level of education you completed? 
o  Elementary school only 
o  Some high school, but did not finish 
o  Completed high school 
o  Some college, but did not finish 
o  Two-year college degree / A.A / A.S. 
o  Four-year college degree / B.A. / B.S. 
o  Some graduate work 
o  Completed Masters or professional degree 
o  Advanced Graduate work or Ph.D. 
 
Apart from events such as weddings and funerals, how often do you attend religious services? 
o  More than once a week  
o  Once a week  
o  Once or twice a month  
o  A few times a year  
o  Never 
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Appendix F: Brief Fatigue Inventory 
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Appendix G: Authorization to Use Brief Fatigue Inventory 
 
 
From: symptomresearch [symptomresearch@mdanderson.org] 
Sent: Friday, July 26, 2013 10:17 AM 
To: Tinsley, Sara M. 
Cc: symptomresearch 
Subject: RE: Order Form for Department of Symptom Research Assessment Tools 
 
Hello Sara, 
 
I have attached the BFI as you requested. Please let me know if you have any questions. Thank 
you for your interest in the BFI. 
 
The email that is sent with the tool is the authorization letter for all the non-funded academic 
research, clinical practice or educational purpose. 
 
Regards, 
 
Mary Samad 
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Appendix H: FACT Leukemia Questionnaire 
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Appendix I: FACT-Leu Licensing Agreement  
 
FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT) LICENSING AGREEMENT 
 
July 24, 2013 
 
The Functional Assessment of Chronic Illness Therapy system of Quality of Life questionnaires and all related 
subscales, translations, and adaptations (“FACIT System”) are owned and copyrighted by David Cella, Ph.D.  The 
ownership and copyright of the FACIT System - resides strictly with Dr. Cella. Dr. Cella has granted FACIT.org 
(Licensor) the right to license usage of the FACIT System to other parties. Licensor represents and warrants that it 
has the right to grant the License contemplated by this agreement. Licensor provides to Moffitt Cancer Center the 
licensing agreement outlined below.  
 
This letter serves notice that Moffitt Cancer Center and all its affiliates (as defined below) (“COMPANY”) are 
granted license to use the English version of the FACT-Leu in one study.  
 
“Affiliate” of (COMPANY) shall mean any corporation or other business entity controlled by, controlling or under 
common control with (COMPANY) For this purpose “control” shall mean direct or indirect beneficial ownership of 
fifty percent (50%) or more of the voting or income interest in such corporation or other business entity.  
 
This current license extends to (COMPANY) subject to the following terms: 
 
1) (COMPANY) agrees to provide Licensor with copies of any publications which come about as the result of 
collecting data with any FACIT questionnaire. 
 
2) Due to the ongoing nature of cross-cultural linguistic research, Licensor reserves the right to make adaptations 
or revisions to wording in the FACIT, and/or related translations as necessary. If such changes occur, (COMPANY) 
will have the option of using either previous or updated versions according to its own research objectives. 
 
3) (COMPANY) and associated vendors may not change the wording or phrasing of any FACIT document without 
previous permission from Licensor. If any changes are made to the wording or phrasing of any FACIT item without 
permission, the document cannot be considered the FACIT, and subsequent analyses and/or comparisons to other 
FACIT data will not be considered appropriate. Permission to use the name “FACIT” will not be granted for any 
unauthorized translations of the FACIT items. Any analyses or publications of unauthorized changes or translated 
versions may not use the FACIT name. Any unauthorized translation will be considered a violation of copyright 
protection. 
 
4) In all publications and on every page of the FACIT used in data collection, Licensor requires the copyright 
information be listed precisely as it is listed on the questionnaire itself. 
 
5) This license is not extended to electronic data capture vendors of (COMPANY). Electronic versions of the 
FACIT questionnaires are considered derivative works and are not covered under this license. Permission for use of 
an electronic version of the FACIT must be covered under separate agreement between the electronic data capture 
vendor and FACIT.org  
 
6) This license is only extended for use on the internet on servers internal to (COMPANY). This FACIT license 
may not be used with online data capture unless specifically agreed to by Licensor in writing. Such agreement will 
only be provided in cases where access is password protected.  
 
7) Licensor reserves the right to withdraw this license if (COMPANY) engages in scientific or copyright misuse of 
the FACIT system of questionnaires.  
 
8) There are no fees associated with this license. 
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Appendix J: Informed Consent 
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